Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01796470 · ClinicalTrials.gov registry record · Phase 2
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT01796470 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 66 participants.
The verdict
NCT01796470, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy of the combination entospletinib and idelalisib in participants with relapsed or refractory hematologic malignancies. Participants will be enrolled who have one of the following hematological tumor types: chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), or indolent non-Hodgkin lymphomas (iNHL; including follicular lymphoma (FL) and lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia \[LPL/WM\], small lymphocytic lymphoma \[SLL\], or marginal zone lymphoma \[MZL\]).
Interventions
- DRUG Idelalisib
- DRUG Entospletinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2013-06-20 |
| Est. Completion | 2016-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01796470
The ClinicalTrials.gov registry entry for NCT01796470 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Idelalisib is the first listed.
NCT01796470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01796470 about?
NCT01796470 is a clinical study titled "Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies". This study will evaluate the efficacy of the combination entospletinib and idelalisib in participants with relapsed or refractory hematologic malignancies. Participants will be enrolled who have one of the following hematological tumor types: chronic lymphocytic leukemia (CLL), mantle cell lymphoma ...
What is the current status of trial NCT01796470?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2013-06-20. Estimated completion is 2016-12-22.
What interventions are being tested in trial NCT01796470?
The interventions under investigation include: Idelalisib (DRUG), Entospletinib (DRUG).
Who is sponsoring clinical trial NCT01796470?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.